Pomerantz LLP

Please read and download this complaint. When you have finished, continue to Join this ACTION >>

Questions? Contact Us

Tyme Technologies, Inc.

Pomerantz LLP is investigating claims on behalf of investors of Tyme Technologies, Inc. ("Tyme or the "Company").

Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Tyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

On January 18, 2019, Tyme reported results from an open-label Phase 2 clinical trial evaluating the Company's product candidate SM-88 in patients with end-stage pancreatic cancer. Although Tyme characterized the results as positive, stating that SM-88 "improves survival," the trial did not include a control group, and Tyme's announcement merely compared survival data to historical controls. On this news, Tyme's stock price fell $1.32 per share, or 35.39%, to close at $2.41 per share on January 18, 2019.